PMID- 25054118
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20140723
LR  - 20211021
IS  - 2305-7823 (Print)
IS  - 2305-7823 (Electronic)
IS  - 2305-7823 (Linking)
VI  - 2014
IP  - 1
DP  - 2014
TI  - HEAT-PPCI: A clear and welcome win for heparin.
PG  - 40-4
LID - 10.5339/gcsp.2014.7 [doi]
AB  - The use of bivalirudin during primary percutaneous coronary intervention (PPCI) 
      is perceived to be associated with less bleeding compared to unfractionated 
      heparin (UFH). However, evidence supporting this observation is confounded by the 
      frequent co-administration of glycoprotein IIb/IIIa inhibitors in the UFH arm in 
      the majority of previous large trials. The "How Effective Are Antithrombotic 
      Therapies in Primary PCI (HEAT-PPCI)" trial was conducted to test the efficacy 
      and safety of UFH vesrus bivalirudin in patients undergoing PPCI when GP IIb/IIIa 
      inhibitors are used selectively.
FAU - ElGuindy, Ahmed M
AU  - ElGuindy AM
AD  - Division of Cardiology, Aswan Heart Centre, Egypt.
LA  - eng
PT  - Journal Article
DEP - 20140129
PL  - Qatar
TA  - Glob Cardiol Sci Pract
JT  - Global cardiology science & practice
JID - 101613130
PMC - PMC4104376
OTO - NOTNLM
OT  - HEAT-PPCI
OT  - STEMI
OT  - bivalirudin
OT  - primary PCI
OT  - unfractionated heparin
EDAT- 2014/07/24 06:00
MHDA- 2014/07/24 06:01
PMCR- 2014/01/29
CRDT- 2014/07/24 06:00
PHST- 2014/04/13 00:00 [received]
PHST- 2014/04/16 00:00 [accepted]
PHST- 2014/07/24 06:00 [entrez]
PHST- 2014/07/24 06:00 [pubmed]
PHST- 2014/07/24 06:01 [medline]
PHST- 2014/01/29 00:00 [pmc-release]
AID - gcsp.2014.7 [pii]
AID - 10.5339/gcsp.2014.7 [doi]
PST - epublish
SO  - Glob Cardiol Sci Pract. 2014 Jan 29;2014(1):40-4. doi: 10.5339/gcsp.2014.7. 
      eCollection 2014.